






Supplemental Figure 1. VPA reduces glomerulosclerosis and interstitial fibrosis in *Pod-Cre Dnm1^{fl/fl} Dnm2^{fl/fl}* (*Dnm* DKO) mice. (A) Total HDAC activity in control and *Dnm* DKO glomeruli treated +/- VPA. *p < 0.05 compared to control, and #p < 0.05 compared to *Dnm* DKO mice glomeruli. N=3. (B) Quantification of urine albumin/creatinine ratio in control (black) and *Dnm* DKO mice treated +/- VPA (red: -VPA, blue: +VPA) at 2 to 6 weeks old age. *p < 0.05 compared to control mice, and #p < 0.05 compared to *Dnm* DKO mice with vehicle. N=5. (C) Plasma creatinine levels at 3, 5, and 7 week-old age in control (black) and *Dnm* DKO mice treated +/- VPA (red: -VPA, blue: +VPA). *p < 0.05 compared to control mice, and #p < 0.05 compared to *Dnm* DKO mice with vehicle. N=5. (D) Body weight of control (black) and *Dnm* DKO mice treated +/- VPA (red: -VPA, blue: +VPA) in each group mice. N=5. (E) Survival curve of control (black) and *Dnm* DKO mice treated +/- VPA (red: -VPA, blue: +VPA) in each group mice. N=5. (F) Representative light microscope images (H&E, PAS, and trichrome) from 3 week-old *Dnm* DKO and 6 week-old control and *Dnm* DKO mice glomerulus treated +/- VPA. Arrowheads show mesangial matrix deposition and mesangial cell proliferation. Scale bar: 25 μ m. (G) Representative trichrome staining in 3 week-old *Dnm* DKO mice and 6 week-old control and *Dnm* DKO mice kidney treated +/- VPA. Arrowheads show dilated tubules and proteinaceous casts, and arrows display interstitial fibrosis. Scale bar: 50 μ m. (H) Quantification of glomerulosclerosis in (F). *p < 0.05 compared to control mice, and #p < 0.05 compared to *Dnm* DKO mice with vehicle. (I) Quantification of interstitial fibrosis in (G). *p < 0.05 compared to control mice, and #p < 0.05 compared to *Dnm* DKO mice with vehicle. (A), (B), (C), (H), and (I) Statistically analyzed by one-way ANOVA with Dunnett's correction.




Supplemental Figure 2. VPA reduces glomerulosclerosis and interstitial fibrosis in *Pod-Cre Tln1*^{fl/fl} (*Tln1* KO) mice.

(A) Total HDAC activity in control and *Tln1* KO glomeruli treated +/- VPA. *p < 0.05 compared to control, and #p < 0.05 compared to *Tln1* KO mice glomeruli. N=3. (B) Quantification of urine albumin/creatinine ratio in control (black) and *Tln1* KO mice treated +/- VPA (red: -VPA, blue: +VPA) at 2 to 5 weeks old age. *p < 0.05 compared to control mice, and #p < 0.05 compared to *Tln1* KO mice with vehicle. N=5. (C) Plasma creatinine levels at 3 and 5 weeks old age in control (black) and *Tln1* KO mice treated +/- VPA (red: -VPA, blue: +VPA). *p < 0.05 compared to control mice, and #p < 0.05 compared to *Tln1* KO mice with vehicle. N=5. (D) Body weight of control (black) and *Tln1* KO mice treated +/- VPA (red: -VPA, blue: +VPA) in each group. N=5. (E) Survival curve of control (black) and *Tln1* KO mice treated +/- VPA (red: -VPA, blue: +VPA) in each group. N=5. (F) Representative light microscope images of glomerulus (H&E, PAS, and trichrome) from control, 2 weeks-old *Tln1* KO, and 5 weeks-old *Tln1* KO mice treated +/- VPA. Arrowheads show mesangial matrix deposition and mesangial cell proliferation. Scale bar: 25 μm. (G) Representative trichrome staining in control, 2 weeks-old *Tln1* KO mice, and 5 weeks-old *Tln1* KO mice treated +/- VPA. Arrowheads show dilated tubules and proteinaceous casts, and arrows display interstitial fibrosis. Scale bar: 50 μm. (H) Quantification of glomerulosclerosis in (F). *p < 0.05 compared to control mice, and #p < 0.05 compared to *Tln1* KO mice with vehicle. (I) Quantification of interstitial fibrosis in (G). *p < 0.05 compared to control mice, and #p < 0.05 compared to *Tln1* KO mice with vehicle. (A), (B), (C), (H), and (I) Statistically analyzed by one-way ANOVA with Dunnett's correction.




Supplemental Figure 3. VPA or SAHA reduces urine albumin and glomerular injury induced by NTS or Adriamycin.

(A) Total HDAC activity in NTS or Adriamycin (ADR)-injected mice glomerulus. *p < 0.05 compared to control mice. N=3. (B) Quantification of urine albumin/creatinine ratio at 0, 3, and 10 days after NTS injection treated +/- VPA or SAHA (black: -NTS, red: +NTS, blue: +NTS+VPA, green: +NTS+SAHA). *p < 0.05 compared to control mice, and #p < 0.05 compared to NTS-injected control mice. N=5. (C) Representative light microscope images (H&E, PAS, and trichrome) of glomerulus from NTS-injected mice treated +/- VPA or SAHA. Arrowheads show mesangial matrix deposition and mesangial cell proliferation. Scale bar: 25 μ m. (D) Quantification of urine albumin/creatinine ratio at 0, 1, and 4 weeks after ADR injection treated with vehicle, VPA, or SAHA (black: -ADR, red: +ADR, blue: +ADR+VPA, green: +ADR+SAHA). *p < 0.05 compared to control mice and #p < 0.05 compared to ADR-injected control mice. N=5. (E) Representative light microscope images (H&E, PAS, and trichrome) of glomerulus from ADR-injected mice treated +/- VPA or SAHA. Arrowheads show mesangial matrix deposition and mesangial cell proliferation. Scale bar: 25 μ m. (A) Statistically analyzed by 2-tailed Student's t test. (B) and (D) Statistically analyzed by one-way ANOVA with Dunnett's correction.




Supplemental Figure 4. Normal kidney function is observed in Doxycycline-inducible podocyte specific *Hdac1* and *Hdac2* DKO mice. (A) Representative immunostaining of HDAC1 (green), HDAC2 (green), and WT1 (red) in *Hdac1^{fl/fl} Hdac2^{fl/fl} Pod-rtTA TetO-Cre* mice glomerulus after completing Dox induction. Scale bar: 10 μ m. (B) Representative light microscopy images (H&E, PAS, and trichrome) of glomerulus from control and *Hdac1^{fl/fl} Hdac2^{fl/fl} Pod-rtTA TetO-Cre* mice 4 weeks after completing Dox induction. Scale bar: 25 μ m. (C) Representative trichrome staining in control and *Hdac1^{fl/fl} Hdac2^{fl/fl} Pod-rtTA TetO-Cre* mice kidney 4 weeks after completing Dox induction. Scale bar: 50 μ m. (D) Quantification of urine albumin/creatinine ratio in control and *Hdac1^{fl/fl} Hdac2^{fl/fl} Pod-rtTA TetO-Cre* mice 4 weeks after completing Dox induction. N=5. (E) Plasma creatinine in control and *Hdac1^{fl/fl} Hdac2^{fl/fl} Pod-rtTA TetO-Cre* mice 4 weeks after completing Dox induction. N=5.

A




B




Supplemental Figure 5. Doxycycline-inducible podocyte specific *Hdac1* and *Hdac2* DKO mice reduce NTS-induced podocyte injury. (A) Quantification of urine albumin/creatinine ratio at 0 and 7 days after NTS injection in control (black) and *Hdac1^{fl/fl} Hdac2^{fl/fl} Pod-rtTA TetO-Cre* mice (blue). * $p < 0.05$ compared to control mice before NTS injection (day 0), and # $p < 0.05$ compared to control mice treated with NTS (day 7). Statistically analyzed by 2-tailed Student's *t* test. $N=5$.

(B) Representative light microscopy images (H&E, PAS, and trichrome) of glomerulus from control and *Hdac1^{fl/fl} Hdac2^{fl/fl} Pod-rtTA TetO-Cre* mice 7 days after NTS injection. Arrowheads show mesangial matrix deposition and mesangial cell proliferation. Scale bar: 25 μm .



Supplemental Figure 6. Glomerular EGR1 expression increases in mouse models of proteinuria.


(A) RT-PCR of *Adamts5*, *Egr1*, *Itga8*, and *Ptn* in DT-treated *Pod-Cre Rosa-DTR^{fllox}* mice primary podocytes. N=3. (B) Representative immunoblots of EGR1 and WT1 in *Tln1^{fl/fl} Pod-rtTA TetO-Cre* mice glomerulus after completion of Dox induction. (C and D) Representative immunoblots of EGR1 and GAPDH in *Dnm DKO* (C) and *Tln1 KO* (D) mice glomerulus treated +/- VPA. (E) Total HDAC activity in DT-treated *Pod-Cre Rosa-DTR^{fllox}* mice primary podocytes with LPS or PS. *p < 0.05 compared to control. N=3. (F to I) ChIP-assay using SRF antibody and primer sets for *Egr1* promoter 1 in primary podocytes with LPS (F) or PS (G), or for *Egr1* promoter 2 in primary podocytes with LPS (H) or PS (I) treated +/- VPA, or SAHA. DNA binding was determined by PCR. N=3. (E) Statistically analyzed by one-way ANOVA with Dunnett's correction.




Supplemental Figure 7. VPA ameliorated LPS-induced actin cytoskeletal derangement through EGR1 in primary podocytes.

(A) Representative immunostaining for phalloidin (green) and WT1 (red) in control primary podocytes with LPS treated +/- VPA. Scale bar: 10 μ m. (B) Representative immunostaining for GFP (green) and phalloidin (red) in control primary podocytes with LPS and VPA overexpressing GFP-EGR1. Scale bar: 10 μ m. (C) Quantification of phalloidin staining in (A). (black: control, red: LPS +vehicle, and blue: LPS +VPA). * $p < 0.05$ compared to control, and # $p < 0.05$ compared to control primary podocytes with LPS +vehicle. N=3. (D) Quantification of phalloidin staining in (B) (red: GFP positive primary podocytes and blue: GFP negative primary podocytes). * $p < 0.05$ compared to GFP positive primary podocytes. N=3. (E) WT1 positive number per glomerulus in control, and *Tln1^{fl/fl} Pod-rtTA TetO-Cre* mice treated with vehicle or VPA. * $p < 0.05$ compared to control, and # $p < 0.05$ compared to *Tln1^{fl/fl} Pod-rtTA TetO-Cre* mice with vehicle. N=3. (F) Representative immunostaining for TUNEL (green) and WT1 (red) in *Tln1^{fl/fl} Pod-rtTA TetO-Cre* mice kidney 2 weeks after completing Dox induction. Arrowheads show TUNEL positive tubular cells. Scale bar: 20 μ m. (C) and (E) Statistically analyzed by one-way ANOVA with Dunnett's correction. (D) Statistically analyzed by 2-tailed Student's t test.

A



B



Supplemental Figure 8. Deletion of *Egr1* in mice, reduces NTS-induced podocyte injury. (A) Quantification of urine albumin/creatinine ratio at 0 and 7 days after NTS injection in control (black) and *Egr1*^{-/-} (blue) mice. *p < 0.05 compared to control mice before NTS injection (day 0), and #p < 0.05 compared to NTS-injected control mice (day 7) Statistically analyzed by 2-tailed Student's t test. N=5. (B) Representative light microscope images (H&E, PAS, and trichrome) of glomerulus from NTS-injected control and *Egr1*^{-/-} mice. Arrowheads show mesangial matrix deposition and mesangial cell proliferation. Scale.bar: 25 µm.

Supplemental table 1 Gene list from microarray data analysis (*Tln1^{fl/fl} Pod-rtTA TetO* vs control).

Gene symbol	Z ratio (1st batch)	Z ratio (2nd batch)
Gm2431	2.26	2.22
Gm22424	2.23	2.21
Gm4963	2.29	2.13
Trim59	2.18	1.97
Trim34a	2.12	2.01
Gm23609	2.32	2.02
Bmp8a	2.14	2.25
Cdc25b	2.17	2.16
Adamts1	2.06	2.31
Slc26a10	1.97	2.16
Lrtm2	1.97	2.11
Gm22459	2.05	2.13
Gpr137b-ps	2.80	2.35
Jun	2.83	2.30
Olf3	2.76	2.27
E130310I04Rik	2.71	2.40
Mir1949	2.73	2.36
Gm23908	2.73	2.55
Ptn	2.54	2.04
Gm15708	2.47	2.06
Pdgfrb	2.75	2.00
Bcl2a1c	2.18	2.58
Plk2	2.15	2.56
Kctd12b	2.20	2.71

Smim6	2.34	2.62
Igkv12-47	2.36	2.58
Tnfrsf12a	2.50	2.34
Ier2	2.35	2.37
Gm23700	2.71	2.76
Plod2	2.71	2.71
P2ry1	2.56	2.81
Ache	2.59	2.73
S1pr3	3.20	2.73
Olfr1396	3.14	2.67
Vim	3.18	2.50
Adamts5	3.05	2.44
Gm10719	3.47	2.81
Serpini1	3.77	2.39
Phf11b	3.51	2.06
Gm23181	3.22	2.15
n-R5s68	2.77	3.41
Atf3	2.72	3.39
Gm23716	2.64	3.53
Gm24770	2.63	3.23
Mki67	2.22	3.15
Gm23422	2.19	3.13
Mir669m-1	2.32	3.08
Adm	2.25	3.01
Gata5	2.85	3.14
Anxa1	2.85	3.14
Ces2b	2.89	2.92

Tnfsf15	3.12	3.34
Trav9d-3	3.00	3.28
mt-Tc	2.40	3.68
Per3	2.43	3.52
Nfkbie	2.25	3.92
mt-Tt	2.75	3.96
Gm25748	2.58	3.80
Dbp	2.39	4.80
Junb	2.22	4.65
Mrgpra1	2.14	4.43
Dkk2	1.96	4.42
Gm9312	4.40	3.16
Gm10721	4.28	3.07
Gm25568	4.25	3.23
Gm10717	4.20	3.43
n-R5s165	3.85	3.24
Itga2	3.97	2.99
Gm10718	4.54	3.08
LOC102636919	4.72	2.81
Gm10722	4.35	2.92
Gm22323	4.33	2.73
Cyp2a4	5.23	3.76
Des	5.10	3.24
Gm22949	5.11	2.44
Erc2	5.24	1.98
Gm21057	5.70	2.70
Mest	3.19	3.74

Fgfbp1	3.26	3.60
Csgalnact1	3.23	3.91
Olfr935	3.58	3.62
Hspa1b	3.60	4.24
Hspa1a	3.51	4.15
Itga8	3.89	4.06
Stc1	4.06	4.76
mt-Ts2	4.08	4.44
Gm22565	4.57	4.13
mt-Tk	4.44	4.06
Fosb	3.16	5.21
Gadd45b	2.79	5.13
Epha6	2.98	5.66
Cyp4a12b	4.24	5.67
Lcn2	3.62	5.30
Car3	9.60	4.07
Kap	9.72	3.15
Cd36	8.15	3.90
Fos	7.47	5.68
Egr1	6.88	5.34
Npy6r	5.85	5.94
Cyp4a12a	14.27	2.32
Cyp27b1	-9.21	-2.42
Serpina1d	-10.00	-2.31
Ighj4	-9.72	-4.30
Scd1	-9.71	-4.53
Igkv1-110	-7.75	-3.53

Cyp4a14	-6.67	-4.55
Igkj1	-7.44	-4.99
Plekhb1	-7.54	-4.52
Hpd	-7.97	-4.33
Tm6sf2	-4.87	-2.71
Igkv1-135	-4.97	-2.84
Prlr	-4.78	-3.71
Cpn1	-4.67	-4.10
Slitrk1	-6.72	-1.99
Gsta4	-5.60	-2.60
Ighv1-34	-5.88	-2.14
8430408G22Rik	-6.07	-2.06
Slc38a3	-4.61	-5.72
Plk3	-5.63	-4.70
Zbtb16	-5.33	-5.10
Slc16a4	-2.03	-5.09
Cacna2d2	-2.82	-6.24
Igkv10-96	-3.47	-4.99
Angptl4	-2.70	-5.08
Gldc	-3.06	-5.27
Gm25107	-3.46	-3.95
Ugt2b34	-3.61	-3.85
Gm10639	-3.44	-4.25
Hao2	-3.36	-4.18
Hacl1	-3.32	-4.23
Gm3776	-3.10	-3.52
Cyp2c44	-2.62	-2.96

Glul	-2.96	-3.17
Gm8074	-2.73	-3.21
Cdhr2	-2.81	-3.39
Sema3g	-2.34	-3.87
LOC102632854	-2.63	-3.82
Clrn3	-2.31	-4.24
Papss2	-2.33	-4.28
Pla2g10os	-2.05	-3.31
Gm24701	-1.96	-3.45
Reep6	-2.01	-3.73
Elovl2	-2.18	-3.60
Dpep1	-2.18	-3.22
Slc35f1	-2.29	-3.32
Cyp51	-2.39	-3.29
Cyp2d26	-2.47	-3.27
Angptl3	-3.52	-2.16
Gm22502	-3.33	-2.30
Tmem86b	-3.31	-2.49
Epb4.1l3	-2.99	-2.01
Rnf223	-3.10	-1.98
Gm24262	-2.92	-2.20
Slc7a8	-2.78	-2.04
Pim3	-2.70	-2.19
Gc	-4.28	-2.66
Fads1	-3.79	-2.47
Ighg1	-4.01	-2.52
Mfsd7c	-3.64	-3.05

BC089597	-3.53	-3.30
Kynu	-3.94	-2.89
Cyp4a10	-3.94	-3.25
Mir1943	-2.41	-1.98
Slc39a5	-2.58	-1.99
Igkv4-59	-2.45	-2.38
Acaa2	-2.34	-2.29
Rps3	-2.42	-2.26
Gm26448	-2.02	-1.98
Spp2	-2.29	-2.10
Mogat2	-2.28	-2.19
Cypt15	-2.01	-2.16
Gm24727	-2.04	-2.30
Pck1	-2.12	-2.28
Tmem252	-2.17	-2.24
Pdxk	-2.54	-2.54
Snord22	-2.48	-2.69
Snora74a	-2.78	-2.43
Insig1	-2.71	-2.65
Klf15	-2.66	-2.54
Guca2b	-2.71	-2.54
Tkt	-1.99	-2.48
n-R5s136	-1.97	-2.75
Slc7a7	-2.07	-2.88
Gstm7	-2.05	-2.97
Smim24	-2.23	-2.57
Nsdhl	-2.35	-2.79

Lyplal1	-2.22	-2.72
Lpar3	-2.23	-2.79

Supplemental table 2 A list of the top 10 perturbagen using Connectivity Map from the microarray data.

Rank	Perturbagen
1	GW-8510-7810
2	Trichostatin A-2794
3	Trichostatin A-3462
4	H-7-5963
5	Trichostatin A-5231
6	0175029-0000-4713
7	Trichostatin A-4770
8	Valproic acid-1078
9	Trichostatin A-6951
10	Trichostatin A-6064

Supplemental table.3 Gene list from microarray data analysis (Vehicle vs VPA).

Gene symbol	Z ratio (1st batch)	Z ratio (2nd batch)
Olfr494	2.38	2.43
Prex2	2.36	2.43
Ighv8-8	2.34	2.41
Mir335	2.29	2.45
Gm23134	2.25	2.35
Pcdh18	2.45	2.44
Smad6	2.39	2.48
Olfr1396	2.22	2.53
Lgals2	2.17	2.44
Lrtm2	2.15	2.63
Plat	2.06	2.38
Casr	2.05	2.30
Mir1938	2.12	2.25
Adamts5	2.24	2.20
BC117090	2.24	2.18
Egf	2.24	2.15
Mest	2.23	1.99
Ptn	2.20	1.98
Galnt10	2.02	2.12
Rdh1	2.07	1.98
Pdgfd	2.52	2.05
Plac9b	2.45	2.10
Gpsm3	2.42	1.96
Olfr1375-ps1	2.26	3.19

Gata5	2.03	3.11
Trdv2-1	2.12	3.49
Gdf10	2.88	2.22
4930414L22Rik	2.85	2.25
Olfr1238	2.91	2.27
Gm26491	2.98	2.39
Nphs1	2.75	2.37
P2ry1	2.72	2.26
Traj43	2.56	2.34
Hs3st3a1	3.03	1.99
Trdv2-2	2.73	1.97
9030624G23Rik	3.39	2.83
S1pr3	3.39	2.74
Gm23700	3.26	2.50
Cml5	3.34	2.30
Cyp2e1	3.25	3.08
Zfp457	3.22	2.94
Gm22906	3.07	3.12
Gm25379	3.36	3.29
Gm24674	2.64	3.36
Olfm12b	2.58	3.19
Npr3	2.81	3.09
Gm21057	3.03	4.05
mt-Tf	3.18	3.84
2210409E12Rik	3.50	3.80
Kap	2.86	3.75
mt-Ts2	2.84	3.69

Dkk2	2.64	3.92
Dnase1	4.38	2.47
Slc22a26	4.42	2.38
Gm26358	4.21	2.52
Ces1f	4.18	2.30
Gm22565	4.77	2.22
Cyp2d40	5.17	2.89
Lpl	5.02	2.90
Ccrl2	4.46	3.59
Snx31	3.97	3.06
Cyp26b1	4.01	2.92
Ces2b	3.79	2.99
Rbp1	3.85	2.76
Erc2	3.97	3.49
Itga8	3.71	3.26
Cd36	7.18	2.44
Akr1c14	6.53	2.22
Fosb	3.94	6.47
Egr1	4.39	4.93
Ehd3	2.69	5.15
mt-Tt	2.67	4.86
Cyp2a4	6.83	5.53
Fos	5.64	6.48
Cyp24a1	-11.65	-2.59
Fgg	-14.13	-3.98
Gbp2	-2.78	-9.69
8430408G22Rik	-7.11	-3.45

Top2a	-5.52	-3.01
Fga	-5.98	-2.50
Fgb	-6.10	-2.91
Zbtb16	-4.81	-4.81
Gbp3	-2.59	-5.98
C4b	-3.11	-6.64
Gm906	-2.21	-4.81
Rnase1	-2.18	-5.27
Rarres2	-2.75	-4.60
Fbp2	-2.63	-4.77
Gm16010	-2.37	-3.95
Gm11084	-2.58	-3.91
Slc13a1	-2.09	-3.59
Tap1	-2.08	-4.05
Psmb10	-2.09	-4.11
Ndc80	-2.75	-3.40
C7	-2.00	-3.23
Gm25006	-2.11	-2.97
Gm2825	-2.12	-3.09
Nek6	-2.11	-2.69
Pyhin1	-2.00	-2.83
Plac8	-2.43	-2.93
Gm26448	-2.55	-2.85
Gc	-3.96	-2.47
Misp	-3.38	-2.22
Fabp1	-3.42	-2.23
Cybb	-2.80	-2.82

Plk3	-3.08	-2.59
Col1a1	-2.99	-2.71
Laptn5	-2.59	-2.03
Ifnz	-2.66	-2.14
Bcmo1	-2.61	-2.26
Slfn9	-2.83	-1.98
Cdkn1a	-3.07	-2.11
Kif11	-2.97	-2.23
Akr1b8	-2.34	-2.25
Hpgds	-2.46	-2.36
Gm17757	-2.46	-2.58
Mfsd7b	-2.29	-2.53
Gm15772	-2.35	-2.60
Gm23608	-2.04	-2.05
Kif20a	-2.12	-2.00
Igsf6	-2.13	-2.19
Gm25799	-1.97	-2.15
Mvp	-1.99	-2.20
Lgals3bp	-2.19	-2.41
Hist4h4	-2.03	-2.32
Zfp108	-2.07	-2.47
Gm23583	-1.97	-2.42
Gpr110	-2.02	-2.43

Supplemental Table 4. Baseline characteristics of the study population, stratified by VPA exposure.

	Valproic Acid (N=2,269)	No Valproic Acid (N=120,601)	P
Age	47.9 +/- 8.5	50.0 +/- 10.3	<0.0001
Sex			0.08
Female	3.3	2.7	
Male	96.7	97.3	
Race			<0.0001
Black	40.5	40.1	
White	50.1	48.1	
Asian	7.2	8.4	
Other	2.2	3.3	
Viral Status			<0.0001
HIV-/HCV-	69.7	58.2	
HIV+/HCV-	13.1	22.9	
HIV-/HCV+	11.2	9.6	
HIV+/HCV+	5.9	9.4	
Baseline eGFR	94 +/- 23	90 +/- 23	<0.0001
Lithium Exposure	0.09	0.1	0.81
Comparator Drug Exposure	3.4	1.2	<0.0001
Urinalysis Proteinuria			0.39
Missing, none or Trace	87.5	86.9	
1+	10.9	11	
>=2+	1.6	2	
Diabetes Mellitus	55.6	48.2	<0.0001
Liver Disease	9.3	10.2	0.14
Hypertension	81.1	76.6	<0.0001
Congestive Heart Failure	18.3	16.6	0.04
Bipolar Disorder	76.5	21.4	<0.0001
Depression	86.7	61.9	<0.0001
Post-Traumatic Stress Disorder	56.4	29.2	<0.0001
Stroke	13.8	10.8	<0.0001
Epilepsy	33.8	11.7	<0.0001
Headache	48.5	62.3	<0.0001

Numbers are percentages or Mean +/- Standard deviation. HIV: Human Immunodeficiency Virus infection. HCV: Hepatitis C Virus infection. eGFR: Estimated Glomerular Filtration Rate.